190 related articles for article (PubMed ID: 15823453)
1. Rapid onset of tolerance to beta-agonist bronchodilation.
Haney S; Hancox RJ
Respir Med; 2005 May; 99(5):566-71. PubMed ID: 15823453
[TBL] [Abstract][Full Text] [Related]
2. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
Haney S; Hancox RJ
Respir Res; 2005 Sep; 6(1):107. PubMed ID: 16168062
[TBL] [Abstract][Full Text] [Related]
3. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy.
Lipworth BJ; Hall IP; Aziz I; Tan KS; Wheatley A
Clin Sci (Lond); 1999 Mar; 96(3):253-9. PubMed ID: 10029561
[TBL] [Abstract][Full Text] [Related]
4. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
5. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
6. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
7. Salbutamol tolerance to bronchoprotection: course of onset.
Stewart SL; Martin AL; Davis BE; Cockcroft DW
Ann Allergy Asthma Immunol; 2012 Dec; 109(6):454-7. PubMed ID: 23176887
[TBL] [Abstract][Full Text] [Related]
8. Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol.
Lee DK; Jackson CM; Bates CE; Lipworth BJ
Thorax; 2004 Aug; 59(8):662-7. PubMed ID: 15282385
[TBL] [Abstract][Full Text] [Related]
9. Effects of treatment with formoterol on bronchoprotection against methacholine.
Lipworth B; Tan S; Devlin M; Aiken T; Baker R; Hendrick D
Am J Med; 1998 May; 104(5):431-8. PubMed ID: 9626025
[TBL] [Abstract][Full Text] [Related]
10. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment.
Yates DH; Sussman HS; Shaw MJ; Barnes PJ; Chung KF
Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1170-4. PubMed ID: 7551366
[TBL] [Abstract][Full Text] [Related]
11. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
[TBL] [Abstract][Full Text] [Related]
12. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Kalra S; Swystun VA; Bhagat R; Cockcroft DW
Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
[TBL] [Abstract][Full Text] [Related]
13. Formoterol induces tolerance to the bronchodilating effect of Salbutamol following methacholine-provocation test in asthmatic children.
Adler A; Uziel Y; Mei-Zahav M; Horowitz I
Pulm Pharmacol Ther; 2006; 19(4):281-5. PubMed ID: 16169761
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of inhaled formoterol in reversing bronchoconstriction.
Rubin AS; Perin C; Pelegrin L; Fernandes JC; da Silva LC
J Bras Pneumol; 2006; 32(3):202-6. PubMed ID: 17273608
[TBL] [Abstract][Full Text] [Related]
15. Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma.
Yates DH; Worsdell M; Barnes PJ
Am J Respir Crit Care Med; 1997 Sep; 156(3 Pt 1):988-91. PubMed ID: 9310023
[TBL] [Abstract][Full Text] [Related]
16. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.
Jones SL; Cowan JO; Flannery EM; Hancox RJ; Herbison GP; Taylor DR
Eur Respir J; 2001 Mar; 17(3):368-73. PubMed ID: 11405513
[TBL] [Abstract][Full Text] [Related]
17. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.
Cheung D; Timmers MC; Zwinderman AH; Bel EH; Dijkman JH; Sterk PJ
N Engl J Med; 1992 Oct; 327(17):1198-203. PubMed ID: 1357550
[TBL] [Abstract][Full Text] [Related]
19. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol.
Ramsdale EH; Otis J; Kline PA; Gontovnick LS; Hargreave FE; O'Byrne PM
Am Rev Respir Dis; 1991 May; 143(5 Pt 1):998-1001. PubMed ID: 1673830
[TBL] [Abstract][Full Text] [Related]
20. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.
van Veen A; Weller FR; Wierenga EA; Jansen HM; Jonkers RE
Pulm Pharmacol Ther; 2003; 16(3):153-61. PubMed ID: 12749831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
